Payment overview · 2025
General Payments
$655.35
18 reported records · 8 companies
Healthcare provider profile · identity verified
Benjamin Leggio, MD
Allopathic & Osteopathic Physicians|Family Medicine · MANSFIELD, LA · NPI 1851370332
Verified facts
What the public records show
CMS Open Payments records show Benjamin Leggio, MD received $655.35 in general payments during 2025 across 18 reported records.
Insulet Corporation accounted for 49.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $325.39 | 49.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 19.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.53 | 7.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.60 | 7.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.70 | 5.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.55 | 5.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.40 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.18 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $655.35 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $325.39 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $47.60 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $35.70 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.55 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
93 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
321 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1467 | 308 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1166 | 223 |
| Losartan Potassium | Losartan Potassium | 959 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 755 | 122 |
| Omeprazole | Omeprazole | 744 | 154 |
| Gabapentin | Gabapentin | 721 | 130 |
| Metformin Hcl | Metformin Hcl | 569 | 112 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 502 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 477 | 95 |
| Lisinopril | Lisinopril | 476 | 101 |
| Furosemide | Furosemide | 472 | 107 |
| Hydralazine Hcl | Hydralazine Hcl | 442 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 422 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 76 |
| Meloxicam | Meloxicam | 373 | 100 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 365 | 104 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 364 | 96 |
| Potassium Chloride | Potassium Chloride | 351 | 78 |
| Clonidine Hcl | Clonidine Hcl | 339 | 59 |
| Carvedilol | Carvedilol | 338 | 66 |
| Eliquis | Apixaban | 321 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 298 | 133 |
| Clopidogrel | Clopidogrel Bisulfate | 296 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 283 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 282 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 280 | 51 |
| Jardiance | Empagliflozin | 266 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 260 | 61 |
| Nifedipine Er | Nifedipine | 250 | 45 |
| Montelukast Sodium | Montelukast Sodium | 221 | 45 |
| Promethazine Hcl | Promethazine Hcl | 217 | 102 |
| Trazodone Hcl | Trazodone Hcl | 213 | 42 |
| Donepezil Hcl | Donepezil Hcl | 205 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 201 | 38 |
| Allopurinol | Allopurinol | 200 | 39 |
| Glipizide | Glipizide | 199 | 37 |
| Levetiracetam | Levetiracetam | 196 | 21 |
| Ozempic | Semaglutide | 193 | 34 |
| Cephalexin | Cephalexin | 187 | 145 |
| Buspirone Hcl | Buspirone Hcl | 186 | 24 |
| Atenolol | Atenolol | 181 | 33 |
| Azithromycin | Azithromycin | 170 | 134 |
| Ibuprofen | Ibuprofen | 162 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 160 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 159 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 154 | 23 |
| Methylprednisolone | Methylprednisolone | 148 | 108 |
| Alprazolam | Alprazolam | 146 | 29 |
| Clonazepam | Clonazepam | 146 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 20 |
| Mupirocin | Mupirocin | 138 | 69 |
| Simvastatin | Simvastatin | 137 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 38 |
| Spironolactone | Spironolactone | 133 | 27 |
| Sertraline Hcl | Sertraline Hcl | 130 | 30 |
| Ezetimibe | Ezetimibe | 126 | 21 |
| Farxiga | Dapagliflozin Propanediol | 115 | 17 |
| Divalproex Sodium | Divalproex Sodium | 114 | 13 |
| Memantine Hcl | Memantine Hcl | 114 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 79 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 111 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 104 | 48 |
| Trulicity | Dulaglutide | 103 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 20 |
| Januvia | Sitagliptin Phosphate | 94 | 12 |
| Linzess | Linaclotide | 93 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 19 |
| Risperidone | Risperidone | 93 | 13 |
| Finasteride | Finasteride | 89 | 15 |
| Pregabalin | Pregabalin | 89 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 15 |
| Methocarbamol | Methocarbamol | 87 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 15 |
| Ondansetron Odt | Ondansetron | 83 | 30 |
| Nabumetone | Nabumetone | 81 | 29 |
| Nitroglycerin | Nitroglycerin | 81 | 33 |
| Amoxicillin | Amoxicillin | 80 | 56 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 37 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 77 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 76 | 55 |
| Bumetanide | Bumetanide | 74 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 73 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 73 | 14 |
| Estradiol | Estradiol | 71 | 15 |
| Glimepiride | Glimepiride | 71 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 69 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | suppressed |
| Chlorthalidone | Chlorthalidone | 68 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 18 |
| Fluconazole | Fluconazole | 68 | 39 |
| Aripiprazole | Aripiprazole | 67 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | suppressed |
| Celecoxib | Celecoxib | 64 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 22 |
| Lorazepam | Lorazepam | 64 | 14 |
| Prednisone | Prednisone | 64 | 16 |
| Mirtazapine | Mirtazapine | 59 | 13 |
| Digoxin | Digoxin | 58 | suppressed |
| Famotidine | Famotidine | 56 | 16 |
| Mounjaro | Tirzepatide | 55 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | 14 |
| Telmisartan | Telmisartan | 54 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 53 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 53 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 53 | suppressed |
| Naproxen | Naproxen | 53 | 18 |
| Baclofen | Baclofen | 52 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 14 |
| Labetalol Hcl | Labetalol Hcl | 51 | suppressed |
| Rexulti | Brexpiprazole | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Novolin R | Insulin Regular, Human | 50 | 16 |
| Olanzapine | Olanzapine | 50 | suppressed |
| Colchicine | Colchicine | 49 | 16 |
| Perphenazine | Perphenazine | 49 | suppressed |
| Glipizide Er | Glipizide | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 45 | 13 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 43 | 17 |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | 28 |
| Valsartan | Valsartan | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Methimazole | Methimazole | 40 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 18 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 38 | 13 |
| Ketoconazole | Ketoconazole | 38 | 18 |
| Humulin R | Insulin Regular, Human | 37 | 14 |
| Hydrocortisone | Hydrocortisone | 35 | 11 |
| Anastrozole | Anastrozole | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Novolog | Insulin Aspart | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Flurbiprofen | Flurbiprofen | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 23 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 23 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 21 | 11 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Austedo | Deutetrabenazine | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $655.35 · 18 records | Insulet Corporation | ABRYSVO, Auvelity, COMIRNATY, DALVANCE, Dexcom G6 Transmitter, FARXIGA, INGREZZA, OMNIPOD, PREVNAR 20, REPATHA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error